Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

45.46 +1.83 (+4.19%)
Streaming Delayed Price Updated: 3:46 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts ↗
 
Via Benzinga
News headline image
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 ↗
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Recap: Veracyte Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Veracyte ↗
 
Via Benzinga
News headline image
Veracyte: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Veracyte Announces First Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally ↗
On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares. 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
News headline image
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed ↗
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ: 
Via Benzinga
News headline image
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
News headline image
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 22, 2024 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes Acquisition of C2i Genomics
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares ↗
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO). 
Via Benzinga
Topics ETFs
News headline image
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
From Veracyte, Inc.
Via Business Wire
News headline image
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
News headline image
Veracyte Announces Third Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.